ALS patients in Europe will soon become the first people in the world to live with a fully implantable wireless brain-computer interface that streams broadband neural data through their skin via an infrared optical link. ABILITY Neurotech, the Geneva-based startup that spun out of the Wyss Center for Bio and Neuroengineering in January 2025, announced on 26 May 2026 that it has received Investigational Medical Device Dossier (IMDD) approval from the Medical Research Ethics Committee (MREC) NedMec in the Netherlands to begin the first chronic implantation study of its device in ALS patients. The study will be conducted at UMC Utrecht under the INTRECOM consortium, which brings together UMC Utrecht, the Technical University of Graz, ABILITY Neurotech, and German implant manufacturer CorTec. The approval moves ABILITY from intra-operative testing into long-term human use, the next-generation step the fully implantable BCI category has been working toward.

What ABILITY has built

ABILITY’s device is a fully implantable wireless optical-link ECoG BCI. The system sits sub-scalp (under the skin of the head, not penetrating the brain tissue itself) and records broadband neural activity from an electrocorticography (ECoG) electrode array placed on the surface of the brain. The signature engineering claim is a 50 Mb/s transcutaneous optical data link, an infrared communication channel that streams raw, broadband neural data out of the implant through the scalp at a fidelity not previously achieved in a fully implantable battery-free device.

The architecture choice has several practical consequences. The implant is battery-free, which removes the rechargeability and replacement cycle that has constrained other long-term implantable neural devices. The optical link bypasses the bandwidth limits of standard radio-frequency wireless telemetry, opening the door to streaming raw neural data continuously rather than transmitting pre-processed summaries. The sub-scalp placement is minimally invasive relative to penetrating intracortical arrays. The whole architecture is designed for chronic long-term use, with comfort and safety profiles intended to support home-use BCI in routine living conditions rather than purely in clinical settings.

The company has spent more than eight years developing the platform and has invested approximately $50 million. CEO Rotem Kopel framed the chronic implantation approval as the moment the field moves from controlled-environment proof points into the practical and scalable system patients can use independently in everyday life.

The INTRECOM consortium

The chronic study will run at UMC Utrecht (University Medical Center Utrecht), one of Europe’s leading clinical BCI centres. The clinical lead is Mariska Vansteensel, PhD, who has led prior implantable BCI work at UMC Utrecht and is a recognised voice on chronic implantable BCI for locked-in patients. The INTRECOM consortium structure brings together UMC Utrecht as the clinical site, the Technical University of Graz in Austria as a planned follow-up site, ABILITY Neurotech as the device sponsor, and CorTec as the German implantable-electronics manufacturer covered in Inside BCI’s 23 April Brain Interchange piece.

The initial protocol uses ALS patients as the first chronic-implant cohort. ALS is one of the most aggressive forms of motor neuron disease and produces total loss of voluntary motor control while leaving cognition intact (the locked-in state). It is the patient population where the marginal value of a high-bandwidth fully implantable BCI is highest, and where the BCI field has historically benchmarked its early clinical work (Pancho and Ann Johnson at UCSF, the Stentrode early Synchron implants, BrainGate’s long-running ALS cohort).

The study is designed to evaluate the platform’s performance as a home-use system for restoring communication and speech, with the longer-term roadmap extending to autonomous text generation, interaction with assistive technologies, and real-time communication directly from a patient’s neural intent.

Where ABILITY sits in the European BCI cluster

ABILITY’s announcement extends a pattern visible across the European BCI cohort over the past two months. It is the third Wyss Center / EPFL / Campus Biotech Geneva-adjacent company Inside BCI has covered, alongside Neurosoft Bioelectronics (Lacour lab spinout, $7.5 million seed on 20 May) and ONWARD Medical (Courtine / Bloch spinout, NASDAQ and Euronext listed, Q1 2026 results yesterday). ABILITY’s involvement of CorTec (German implantable electronics) extends the European supply-chain framing further.

The pattern is consistent: European publicly-funded research institutions are producing commercial-stage BCI companies in close coordination with European clinical sites and European supply-chain partners. ABILITY’s parallel intra-operative evaluation programme at the Technical University of Munich, combined with the chronic study at UMC Utrecht and the planned follow-up at Medical and Technical Universities of Graz, gives the company a four-country European clinical footprint (Switzerland HQ, Netherlands chronic site, Austria follow-up, Germany intra-operative).

What to watch

The first signal is the first chronic implantation surgery date at UMC Utrecht. The IMDD approval clears the regulatory pathway, but the actual surgery date determines when the chronic clinical data begins to accumulate. The second signal is ABILITY’s progression on its FDA Breakthrough Device Designation pathway (currently pending). A dual EU MDR + FDA Breakthrough trajectory positions the company for parallel European and US commercial pathways. The third signal is whether the 50 Mb/s optical-link architecture performs at specification in human chronic use, which is the technical claim the company’s entire commercial thesis is built on.

Sources

• ABILITY Neurotech Receives IMDD Approval (PR Newswire, 26 May 2026)
• Ability Neurotech can begin study of BCI in ALS patients (MassDevice)
• ABILITY (Wyss Center for Bio and Neuroengineering project page)
• ABILITY Neurotech company website
• Ability Neurotech looks to bring ‘mature’ implant to BCI market (MassDevice profile)
• Ability Neurotech says its BCI system’s electrodes and speed set it apart (Medical Design and Outsourcing)